Edition:
United States

aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Global Select Market

3.90USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
11,383
52-wk High
$6.45
52-wk Low
$2.12

Latest Key Developments (Source: Significant Developments)

aTyr Pharma reports qtrly ‍net loss per share, basic and diluted $0.43​
Tuesday, 14 Nov 2017 04:05pm EST 

Nov 14 (Reuters) - aTyr Pharma Inc ::aTyr Pharma announces third quarter 2017 operating results and provides corporate update.aTyr Pharma Inc - ‍expects that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into middle of 2019​.aTyr Pharma Inc qtrly ‍net loss per share, basic and diluted $0.43​.Q3 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Atyr Pharma says ‍John Mendlein transitions from CEO to non-executive board member​
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Atyr Pharma Inc ::Atyr Pharma announces leadership transition.Atyr Pharma Inc - ‍John Mendlein transitions from CEO to non-executive board member​.Atyr Pharma Inc - ‍Sanjay Shukla appointed president and CEO​.  Full Article

Atyr Pharma files for resale of up to 23.6 mln shares of common stock by selling stockholders - SEC Filing‍​
Thursday, 14 Sep 2017 05:44pm EDT 

Sept 14 (Reuters) - Atyr Pharma Inc :Atyr Pharma Inc files for resale of up to 23.6 million shares of common stock by selling stockholders - SEC Filing‍​.  Full Article

‍Viking Global Investors reports 9.5 pct passive stake in aTyr Pharma​
Monday, 11 Sep 2017 06:43am EDT 

Sept 11 (Reuters) - Atyr Pharma Inc :‍Viking Global Investors Lp reports 9.5 percent passive stake in aTyr Pharma Inc as on August 31, 2017 - SEC filing​.  Full Article

Atyr Pharma announces $45 million equity financing
Monday, 28 Aug 2017 07:30am EDT 

Aug 28 (Reuters) - Atyr Pharma Inc :Atyr Pharma announces $45 million equity financing.Investors agreed to purchase 5.9 million shares of common stock at $2.65 per share.Private placement is being led by Viking Global Investors with participation from ECOR1 Capital and Redmile Group.Expects to use proceeds from transaction to advance pipeline of Innovative Therapeutic candidate programs based on knowledge of Resokin Pathway​.Viking Global Investors has also agreed to purchase 2.3 million shares of non-voting class X preferred stock at $13.25 per share.  Full Article

Atyr Pharma qtrly ‍net loss per share $0.51​
Monday, 14 Aug 2017 04:05pm EDT 

Aug 14 (Reuters) - Atyr Pharma Inc ::Atyr Pharma announces second quarter 2017 operating results and provides an update on innovative immunology pipeline.Atyr Pharma Inc qtrly ‍net loss per share, basic and diluted $0.51​.Atyr Pharma Inc - expects that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into Q3 of 2018.Atyr Pharma Inc - ‍plans to commence a phase 1 clinical program for imod.fc program later this year​.  Full Article

ATyr pharma enters into first amendment to loan and security agreement
Wednesday, 5 Jul 2017 04:21pm EDT 

July 5 (Reuters) - ATyr Pharma Inc -:ATyr Pharma says on june 30, entered into first amendment to loan and security agreement with silicon valley bank and solar capital ltd - SEC filing.ATyr Pharma -amendment provides up to $5.0 million in second tranche of term loans may be drawn down at any time before earlier of June 30, or event of default.ATyr Pharma - amendment provides additional $5 million in third tranche of term loans may be drawn down at any time after june 30, before earlier of Dec 31, 2017.ATyr Pharma Inc- in connection with loan amendment, second tranche of $5.0 million was funded on June 30, 2017.  Full Article

aTyr Pharma announces qtrly net loss per share, basic and diluted $0.56
Thursday, 11 May 2017 04:05pm EDT 

May 11 (Reuters) - aTyr Pharma Inc :aTyr Pharma announces first quarter 2017 operating results.aTyr Pharma Inc - Qtrly net loss per share, basic and diluted $0.56.aTyr Pharma Inc- As of March 31, 2017, aTyr had $61.9 million in cash, cash equivalents and investments.aTyr Pharma- Continues to expect that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into Q3 of 2018.Q1 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.  Full Article

Atyr Pharma announces promising top-line results from Resolaris
Monday, 24 Apr 2017 07:30am EDT 

April 24 (Reuters) - Atyr Pharma Inc :Atyr Pharma announces promising top-line results from Resolaris phase 1B/2 clinical trial in patients with early onset facioscapulohumeral muscular dystrophy.Resolaris generally well-tolerated at doses up to 3.0 mg/kg once weekly in early onset facioscapulohumeral muscular dystrophy.Atyr believes observed safety results of Resolaris to date are supportive of further advancement of resolaris.  Full Article

aTyr Pharma qtrly net loss per share attributable to common stockholders $0.53
Thursday, 16 Mar 2017 04:05pm EDT 

aTyr Pharma Inc : Atyr pharma -continues to expect that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into q3 of 2018 . Atyr pharma announces fourth quarter and year-end 2016 operating results . Qtrly net loss per share attributable to common stockholders$0.53 .Q4 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-aTyr Pharma reports qtrly ‍net loss per share, basic and diluted $0.43​

* aTyr Pharma announces third quarter 2017 operating results and provides corporate update